Year-to-date revenue increased 16% while Adjusted EBITDA loss improves 53% quarter over quarter
BOSTON--(BUSINESS WIRE)--November 10, 2025--
908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended September 30, 2025.
"We are pleased with our year-to-date progress as we continue to build a more predictable and profitable business and bring our 908 Devices 2.0 vision to life," said Kevin J. Knopp, CEO and Co-founder. "Revenue for the first nine months increased 16%, with strong FTIR demand and with 47% of revenues coming from our U.S. state and local channel. This product and channel diversity strengthens our run-rate foundation and reduces reliance on the timing of larger U.S. federal and defense enterprise awards. Q3 also reflects the structural improvements we have made to our cost base, resulting in our best Adjusted EBITDA performance in our public company history, positioning us to reach positive Adjusted EBITDA in Q4. While the U.S. Government shutdown may affect the timing of certain awards and shipments, our demand outlook and strategic progress remain strong."
Recent Highlights
-- Revenue of $38.8 million for the first nine months of 2025, increasing
16% compared to first nine months of 2024
-- Revenue of $14.0 million for the third quarter 2025, decreasing 4% year
over year
-- Recurring revenue was $4.8 million, increasing 10% year over year, and
representing 35% of total revenues in the quarter
-- U.S. state and local channel revenue accounted for 47% of our revenues
for the first nine-months of 2025, supporting our strategy to expand more
predictable, run-rate demand relative to the variable timing of large
U.S. federal and defense enterprise deals
-- Delivered strong quarter over quarter improvement in Adjusted gross
margin and Adjusted EBITDA loss, reflecting operational initiatives
-- Adjusted gross margin of 58%, a 190 basis point improvement
quarter over quarter
-- Adjusted EBITDA loss of $1.8 million, improving 53% quarter over
quarter
-- Gained significant momentum in our FTIR portfolio with a record 30%
quarter over quarter increase in XplorIR placements, and with initial
shipments of VipIR, our new 3-in-1 handheld chemical analyzer
-- Ended the quarter with a strong balance sheet, maintaining a significant
cash position of $112.1 million
Third Quarter 2025 Financial Results
In light of the divestiture of the bioprocessing product portfolio in March 2025, all financial results discussed in this release for current and prior periods are for continuing operations only.
Revenue was $14.0 million for the three months ended September 30, 2025, a 4% decrease over the prior year period, largely driven by a decrease in handheld product and service revenue resulting from fewer mass spec device placements. OEM and funded partnership revenue was $0.8 million, compared to $0.5 million in the prior year period. The installed base grew 27% year-over-year to 3,512 devices, with 176 devices placed during the third quarter. Recurring revenue represented 35% of total revenues in the quarter.
Gross profit was $7.4 million for the third quarter of 2025, compared to $7.8 million for the corresponding period in the prior year. GAAP gross margin was 53% as compared to 54% for the corresponding prior year period. Adjusted gross profit was $8.1 million for the third quarter of 2025, compared to $8.5 million for the corresponding period in the prior year. Adjusted gross margin was 58%, a decrease of approximately 60 basis points compared to the corresponding prior year period. The decrease in adjusted gross margin percentage was primarily driven by mix where material costs were a higher percent of product revenues.
Operating expenses were $23.7 million for the third quarter of 2025, compared to $32.3 million for the corresponding prior year period. This decrease was driven by the $30.5 million charge for an impairment of goodwill in the third quarter of 2024, offset in part by a $22.8 million change in the fair value of the contingent consideration liability where it was a charge in the third quarter of 2025 and a credit in the third quarter of 2024.
Net loss from continuing operations was $14.9 million for the third quarter of 2025, compared to a net loss from continuing operations of $23.6 million for the corresponding prior year period. Adjusted EBITDA was a loss of $1.8 million for the third quarter of 2025, compared to $2.7 million for the corresponding period in the prior year.
Net loss attributable to common stockholders was $15.0 million for the third quarter of 2025, compared to a net loss of $29.3 million for the corresponding prior year period.
Cash, cash equivalents and marketable securities were $112.1 million as of September 30, 2025, with no debt outstanding.
2025 Guidance
908 Devices continues to expect full year 2025 revenues from continuing operations to be in the range of $54.0 million to $56.0 million, representing 13% to 17% growth compared to 2024 revenue from continuing operations.
Webcast Information
908 Devices will host a conference call to discuss the third quarter 2025 financial results before market open on Monday, November 10, 2025 at 8:30 am Eastern Time. A webcast of the conference call can be accessed at https://ir.908devices.com/news-events/events. The webcast will be archived and available for replay for at least 90 days after the event.
About 908 Devices
908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit www.908devices.com.
Non-GAAP Measures of Financial Performance
To supplement the Company's financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measures of financial performance are included in this release and presented with detailed reconciliations to comparable GAAP financial results in the tables below:
-- Adjusted gross profit is defined as gross profit excluding intangible
amortization, acquisition and integration costs, restructuring charges
(including the costs of severance), and non-cash expenses related to
stock-based compensation.
-- Adjusted gross margin is defined as adjusted gross profit expressed as a
percentage of total revenue.
-- Adjusted EBITDA is defined as net loss from continuing operations
excluding other income, benefit for income taxes, depreciation,
intangible amortization, acquisition and integration costs, restructuring
charges (including the costs of severance), non-cash expenses related to
stock-based compensation, and costs associated with contingent
consideration related to the Company's acquisitions and for which the
conditions for payment have not yet been achieved.
The Company's non-GAAP financial results presented in this earnings release exclude certain costs that management believes do not have a direct correlation to future business operations, nor do the resulting charges recorded accurately reflect the performance of ongoing operations for the period in which such charges are recorded, nor do the resulting charges recorded accurately reflect the anticipated cash flows of ongoing operations, and as such, excluding these costs allows management to understand and evaluate core operating performance and trends. However, as there are no standardized methods of calculating these non-GAAP financial measures, the Company's methods may differ from those used by other companies in its industry, and accordingly, the use of these measures may not be directly comparable to similar measures used by others, thus limiting their usefulness for purposes of comparison. Furthermore, these non-GAAP measures have certain limitations since they do not include the impact of certain expenses and cash flows that are reflected in the Company's GAAP financial results. Accordingly, when analyzing the Company's operating performance and guidance, investors should not consider non-GAAP measures in isolation or as a substitute for, or superior to, comparable financial measures prepared in accordance with GAAP. Rather, the Company believes that these non-GAAP financial measures, when viewed in addition to and not in lieu of reported GAAP financial results, provide investors with additional meaningful information to assess financial performance and trends, enable comparison of financial results between periods, and allow for greater transparency with respect to key metrics utilized internally in analyzing and operating the Company's business.
Forward Looking Statements
(MORE TO FOLLOW) Dow Jones Newswires
November 10, 2025 07:00 ET (12:00 GMT)
Comments